Physician profile
Thomas Rayner
NPI 1194008979
$60,257.21
in general payments reported to CMS, 2019-2025
12 companies · $55K in 2025
The $55K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.87 · 2023: $4,009 · 2024: $710 · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Debt Forgiveness: $24K · Travel and Lodging: $5,084 · Food and Beverage: $3,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,020.00 |
| Debt Forgiveness | $24,375.00 |
| Travel and Lodging | $5,084.26 |
| Food and Beverage | $3,685.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31,349.88 | 2023-2025 | Spravato, Invega Sustenna |
| Neuronetics, INC. | $28,113.25 | 2023-2025 | Neurostar Tms Therapy System |
| Janssen Scientific Affairs, LLC | $200.49 | 2024 | Spravato |
| Alkermes, INC. | $192.20 | 2022-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $167.14 | 2023-2025 | Uzedy |
| Abbvie INC. | $82.04 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $32.27 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $30.89 | 2024 | Ingrezza |
| Recordati_rare_diseases_inc. | $30.23 | 2024 | Isturisa, Signifor Lar |
| Bioxcel Therapeutics, INC. | $24.56 | 2023 | Igalmi |
| Indivior INC. | $18.48 | 2024 | Perseris |
| Biogen, INC. | $15.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.